Form 4: Fortress Biotech Boosts MBIO Stake with Dividend Shares

Fortress Biotech, a 10% owner and director, acquired 278,385 shares of Mustang Bio common stock as a 2025 annual dividend, increasing its total beneficial ownership to 536,577 shares.

Summary

• Fortress Biotech, Inc. (the "Reporting Person"), a 10% owner and director of Mustang Bio, Inc. (the "Issuer"), reported an acquisition of common stock.
• On January 2, 2026, the Reporting Person acquired 278,385 shares of Mustang Bio common stock.
• This acquisition was an annual dividend for 2025, granted by the Issuer to the Reporting Person.
• The dividend is based on the Reporting Person's Class A Preferred Stock, equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31.
• The shares were acquired at a price of $0 per share, as it was a grant.
• Following this transaction, Fortress Biotech's beneficial ownership in Mustang Bio increased to 536,577 shares.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A major shareholder and director increasing their stake, even through a dividend, indicates continued commitment. The use of a 10b5-1 plan also suggests good governance.

Positives

• A significant shareholder and director, Fortress Biotech, increased its stake in Mustang Bio, signaling continued commitment and confidence.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent trading strategy by the insider.

Future Outlook

The filing reports a past transaction (2025 annual dividend paid in 2026) and does not provide explicit forward-looking statements or guidance regarding future company performance or dividends beyond the nature of the preferred stock dividend entitlement.

Industry Context

This transaction represents a routine insider filing for a dividend payment in shares to a significant shareholder and director. It reflects the ongoing financial relationship between Mustang Bio and Fortress Biotech, a common occurrence in companies with complex ownership structures or strategic partnerships. The payment in shares rather than cash can be a strategy to conserve cash while fulfilling dividend obligations.

Corporate Governance

Related Party Transactions

• Fortress Biotech, Inc., as a 10% owner and director of Mustang Bio, Inc., received an annual dividend in the form of common stock from the Issuer. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The issuance of new shares for the dividend could result in minor dilution for existing common shareholders. However, the increased stake by a major shareholder (Fortress Biotech) may be viewed as a positive signal of confidence in the company's future.
• Company: Fulfilling dividend obligations through share issuance rather than cash helps conserve the company's cash reserves.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-arranged dividend payment in shares to a significant insider. While it increases the insider's stake, it doesn't present new fundamental information that would drastically alter the investment thesis. It reinforces the existing relationship and commitment of a major shareholder, suggesting a 'hold' position for investors who are already invested or considering the stock, pending further operational or financial updates.

Keywords

Fortress Biotech, Mustang Bio, MBIO, SEC Form 4, Insider Transaction, Beneficial Ownership, Dividend, Equity Acquisition, 10% Owner, Director, Rule 10b5-1(c)